Related Experiment Video
Updated: Dec 4, 2025
08:21
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
7.2K
β-Arrestin as a Therapeutic Target in Heart Failure
Leora Boussi1, William H Frishman2
1From the Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
Cardiology in Review
|October 23, 2020
Summary
Beta-arrestin protein shows promise for treating heart failure by regulating G protein-coupled receptor signaling. Developing biased agonists targeting beta-arrestin may offer new therapeutic strategies for this condition.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Heart failure involves maladaptive sympathetic hyperactivity, increasing morbidity and mortality.
- Current therapies targeting beta-adrenergic and angiotensin II receptors have limitations.
- Beta-arrestin is emerging as a key regulator of G protein-coupled receptor (GPCR) signaling.
Purpose of the Study:
- To review the role of beta-arrestin in heart failure.
- To discuss the potential of beta-arrestin-biased GPCR agonists as therapeutics.
- To examine cardiac beta-arrestin isotypes for pharmacotherapeutic development.
Main Methods:
- Review of existing literature on beta-arrestin signaling in heart failure.
- Analysis of GPCR signal transduction pathways involving beta-arrestin.
- Examination of beta-arrestin isotype functions in the heart.
Main Results:
- Beta-arrestin attenuates detrimental GPCR signaling while promoting cardioprotective cascades.
- Beta-arrestin signaling offers potential advantages over traditional heart failure treatments.
- Challenges exist in translating beta-arrestin-targeted therapies to clinical application.
Conclusions:
- Beta-arrestin represents a promising therapeutic target for heart failure.
- Development of beta-arrestin-biased agonists requires careful consideration of isotype diversity.
- Further research is needed to overcome challenges and realize the clinical potential of beta-arrestin-based therapies.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
707
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
707
01:22Heart Failure Drugs: β-Blockers
595
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
595
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
01:25Aortic Regurgitation III: Medical Management
208
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
208
01:17Antihypertensive Drugs: Action of β1 Blockers
1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K